Yoshio Okano

677 total citations
46 papers, 480 citations indexed

About

Yoshio Okano is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, Yoshio Okano has authored 46 papers receiving a total of 480 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pulmonary and Respiratory Medicine, 24 papers in Oncology and 7 papers in Epidemiology. Recurrent topics in Yoshio Okano's work include Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (11 papers) and Lung Cancer Diagnosis and Treatment (7 papers). Yoshio Okano is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (11 papers) and Lung Cancer Diagnosis and Treatment (7 papers). Yoshio Okano collaborates with scholars based in Japan, Germany and United States. Yoshio Okano's co-authors include Masahiko Ando, Tomoya Kawaguchi, Minoru Takada, Atsuhisa Tamura, Yoshio Tomizawa, Yoshifumi Soejima, Hidenori Ibata, Michihiro Yoshimi, Mitsuhiro Kamimura and Akihito Kubo and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

Yoshio Okano

43 papers receiving 471 citations

Peers

Yoshio Okano
Shinsuke Shiotsu Japan
Fuyumi Nishihara Japan
Bruce Kressel United States
Atsushi Takise Japan
Kensaku Ito Japan
Yan-Ping Mao China
Vito Longo Italy
Aline Charabaty United States
Tetsuhiko Itoh Japan
Claire Tissot France
Shinsuke Shiotsu Japan
Yoshio Okano
Citations per year, relative to Yoshio Okano Yoshio Okano (= 1×) peers Shinsuke Shiotsu

Countries citing papers authored by Yoshio Okano

Since Specialization
Citations

This map shows the geographic impact of Yoshio Okano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoshio Okano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoshio Okano more than expected).

Fields of papers citing papers by Yoshio Okano

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yoshio Okano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoshio Okano. The network helps show where Yoshio Okano may publish in the future.

Co-authorship network of co-authors of Yoshio Okano

This figure shows the co-authorship network connecting the top 25 collaborators of Yoshio Okano. A scholar is included among the top collaborators of Yoshio Okano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yoshio Okano. Yoshio Okano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Atagi, Shinji, Takashi Daimon, Kyoichi Okishio, et al.. (2023). A randomized phase III study of docetaxel alone versus docetaxel plus S‐1 in patients with previously treated non‐small cell lung cancer: JMTO LC09‐01. Thoracic Cancer. 14(29). 2941–2949. 1 indexed citations
2.
3.
Takeuchi, Eiji, Kensuke Kondo, Yoshio Okano, et al.. (2023). Pretreatment eosinophil counts as a predictive biomarker in non‐small cell lung cancer patients treated with immune checkpoint inhibitors. Thoracic Cancer. 14(30). 3042–3050. 17 indexed citations
4.
Takeuchi, Eiji, Hirokazu Ogino, Kensuke Kondo, et al.. (2023). An increased relative eosinophil count as a predictive dynamic biomarker in non‐small cell lung cancer patients treated with immune checkpoint inhibitors. Thoracic Cancer. 15(3). 248–257. 7 indexed citations
5.
Takeuchi, Eiji, Kensuke Kondo, Yoshio Okano, et al.. (2022). Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology. 149(7). 3139–3147. 10 indexed citations
6.
Kanazu, Masaki, Mototsugu Shimokawa, Ryusei Saito, et al.. (2022). Predicting systemic therapy toxicity in older adult patients with advanced non-small cell lung cancer: A prospective multicenter study of National Hospital Organization in Japan. Journal of Geriatric Oncology. 13(8). 1216–1222. 4 indexed citations
7.
Kondo, Yoshihiro, Yoshio Okano, Hisanori Machida, et al.. (2022). Favorable response to nivolumab in sarcomatoid malignant pleural mesothelioma: A case report. SHILAP Revista de lepidopterología. 5. 100138–100138. 1 indexed citations
8.
Takeuchi, Eiji, et al.. (2021). Eosinophilic pleural effusion due to lung cancer has a better prognosis than non-eosinophilic malignant pleural effusion. Cancer Immunology Immunotherapy. 71(2). 365–372. 5 indexed citations
9.
Ohji, H., et al.. (2018). Pneumocystis jirovecii pneumonia in an HIV-infected patient mimicking acute eosinophilic pneumonia: a case report with a review of the literature. Journal of Thoracic Disease. 10(11). E774–E778. 4 indexed citations
10.
Shinohara, Tsutomu, et al.. (2016). Disseminated tuberculosis after pregnancy progressed to paradoxical response to the treatment: report of two cases. BMC Infectious Diseases. 16(1). 284–284. 9 indexed citations
11.
Kawaguchi, Tomoya, Masahiko Ando, Kazuhiro Asami, et al.. (2014). Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). Journal of Clinical Oncology. 32(18). 1902–1908. 197 indexed citations
12.
Yoshida, Mitsuteru, et al.. (2012). Cancer of the Left Lung With Persistent Left Superior Vena Cava. The Annals of Thoracic Surgery. 94(4). 1326–1328. 3 indexed citations
13.
Yoshida, Mitsuteru, et al.. (2012). Video-assisted thoracic surgery lobectomy for lung cancer in a patient with complete situs inversus. General Thoracic and Cardiovascular Surgery. 61(3). 155–159. 13 indexed citations
14.
Hanibuchi, Masaki, Fumitaka Ogushi, Yoshio Okano, et al.. (2011). A multi-institutional phase II study of combination chemotherapy with S-1 plus cisplatin in patients with advanced non-small cell lung cancer. Oncology Letters. 2(3). 465–470. 3 indexed citations
15.
Kawaguchi, Tomoya, Minoru Takada, Masahiko Ando, et al.. (2011). A multi-institutional phase II trial of consolidation S-1 after concurrent chemoradiotherapy with cisplatin and vinorelbine for locally advanced non-small cell lung cancer. European Journal of Cancer. 48(5). 672–677. 8 indexed citations
16.
Okano, Yoshio & Makoto Nishio. (2008). [Efficacy of gefitinib in treatment of lung cancer patients with bone metastasis].. PubMed. 18(4). 527–33. 6 indexed citations
17.
Ohyanagi, Fumiyoshi, Atsushi Horiike, Yoshio Okano, et al.. (2007). Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer. Cancer Chemotherapy and Pharmacology. 61(3). 503–508. 14 indexed citations
18.
Ge, Ning, Yasuhiko Nishioka, Yoichi Nakamura, et al.. (2004). Synthesis and Secretion of Interleukin-15 by Freshly Isolated Human Bronchial Epithelial Cells. International Archives of Allergy and Immunology. 135(3). 235–242. 31 indexed citations
19.
Brinkmann, Matthias, et al.. (2003). Glass modification techniques for photonic devices. Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE. 5061. 96–96. 2 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shinsuke Shiotsu Breakdown of academic impact, for papers by Fuyumi Nishihara Breakdown of academic impact, for papers by Bruce Kressel Breakdown of academic impact, for papers by Atsushi Takise Breakdown of academic impact, for papers by Kensaku Ito Breakdown of academic impact, for papers by Yan-Ping Mao Breakdown of academic impact, for papers by Vito Longo Breakdown of academic impact, for papers by Aline Charabaty Breakdown of academic impact, for papers by Tetsuhiko Itoh Breakdown of academic impact, for papers by Claire Tissot
Rankless by CCL
2026